|
[1] WU Z, MCGOOGAN JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China:Summary of a report of 72 314 cases from the Chinese center for disease control and prevention[J]. JAMA,2020.[Online ahead of print]
|
|
[2] Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. An update on epidemiological characteristics of novel coronavirus pneumonia(COVID-19)[J]. Chin J Viral Dis, 2020, 10(2):81-87.(in Chinese）中华预防医学会新型冠状病毒肺炎防控专家组．新型冠状病毒肺炎流行病学特征的最新认识[J]．中国病毒病杂志，2020, 10(2):81-87.
|
|
[3] WONG W, LO YR, JIANG S, et al. Improving the hepatitis cascade:Assessing hepatitis testing and its management in primary health care in China[J]. Fam Pract, 2018, 35(6):731-737.
|
|
[4] Chinese Society of Hepatology and Chinese Society of Infection Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35(12):2670-2686.(in Chinese）中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南（2019年版）[J]．临床肝胆病杂志，2019, 35(12):2670-2686.
|
|
[5] Chinese Society of Infection Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(2019 version)[J]. J Clin Hepatol, 2019, 35(12):2648-2669.(in Chinese）中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南（2019年版）[J]．临床肝胆病杂志，2019, 35(12):2648-2669.
|
|
[6] GHOURI YA, MIAN I, ROWE JH. Review of hepatocel ular carcinoma:Epidemiology, etiology, and carcinogenesis[J]. J Carcinog, 2017, 16(1):1-31.
|
|
[7] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
|
[8] GO H, TANAKA M, YAMAMOTO-MITANI N, et al. Medication adherence among patients with chronic hepatitis receiving antiviral treatment[J]. Gastroenterol Nurs, 2019, 42(2):140-149.
|
|
[9] LI T, LIN QY, HUANG T, et al. Short-term effect of chronic disease patients with long-term prescription policy on the healthcare quality of contracted patients and policy recommendations[J]. Chin Gen Prac, 2017, 20(25):3084-3087.(in Chinese）李婷，林其意，黄涛，等．慢性病长处方政策对签约患者医疗质量的短期影响及政策建议[J]．中国全科医学，2017, 20(25):3084-3087.
|
|
[10] XU K, LIU LM, FARAZI PA, et al. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B[J].Glob Health Action, 2018, 11(1):1433987.
|
|
[11] XU ZJ, QI L, CAI BY, et al. New method for chronic disease management by using social media platform in community hospitals[J]. Chin J Health Educ, 2017, 33(10):957-959.(in Chinese）徐志杰，戚麟，蔡博宇，等．社区医院利用社交媒体平台开展慢性病管理的新思路[J]．中国健康教育，2017, 33(10):957-959.
|
|
[12] ANDREONE P, DI MARCO V, GAETA GB, et al. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection:Assessment of an Italian focus group[J]. Dig Liver Dis, 2019, 51(7):915-921.
|
|
[13] O’ LEARY DA, CROPP E, ISAAC D, et al．“B in IT”-a community-based model for the management of hepatitis B patients in primary care clinics using a novel web-based clinical tool[J]. Hepatol Med Policy, 2018, 3(1):1-10.
|
|
[14] LIU S, HUANG J, FAN J, et al. Fluctuating operation development index of community health service centres in the Pudong new area of Shanghai:A continuous investigation[J]. Int J Health Plann Manage, 2019, 34(1):e679-679, e693.
|
|
[15] DONG JL, HAN XL, LI J, et al. The clinical application of chronic contagious liver disease management mode[J]. J Beijing Med, 2016, 38(9):956-959.(in Chinese）董金玲，韩笑乐，李娟，等．慢性传染性肝病管理模式的临床应用[J]．北京医学，2016, 38(9):956-959.
|
|
[16] SUN X, LI Y, LIU S, et al. Enhanced performance of community health service centers during medical reforms in pudong new district of Shanghai, China:A longitudinal survey[J].PLoS One, 2015, 10(5):e0125469.
|
|
[17] SHIHA G, METWALLY AM, SOLIMAN R, et al. An educate,test, and treat programme towards elimination of hepatitis C infection in Egypt:A community-based demonstration project[J]. Lancet Gastroenterol Hepatol, 2018, 3(11):778-789.
|
|
[18] SU J,YANG Y,YI CT. Practice and reflection about two-way referral of community health service center[J]. Chin Hosp Manage, 2016, 36(5):74-75.(in Chinese）苏瑾，杨恽，易春涛．社区卫生服务中心双向转诊的实践与思考[J]．中国医院管理，2016, 36(5):74-75.
|
|
[19] FELGER JC, COLE SW, PACE TW, et al. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-αtreatment:Relationship with depression and fatigue[J]. Psychol Med, 2012, 42(8):1591-1603.
|
|
[20] de SEVILLA MÁCF, GALLEGOU'BEDA M, HEREDIA BENITO M, et al. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals[J]. Int J Clin Pharm, 2019, 41(2):488-495.
|
|
[21] GOMES LO, TEIXEIRA MR, ROSA J, et al. The benefits of a public pharmacist service in chronic hepattis C treatment:The real-life results of sofosbuvir-based therapy[J]. Res Social Adm Pharm, 2020, 16(1):48-53.
|
|
[22] HAYAT K, LI P, ROSENTHAL M, et al. Perspective of community pharmacists about community-based antimicrobial stewardship programs. A multicenter cross-sectional study from China[J]. Expert Rev Anti Infect Ther, 2019, 17(12):1043-1050.
|
|
[23] QIN SB, ZHANG XY, FU Y, et al. The impact of the clinical pharmacist-led interventions in China:A systematic review and Meta-analysis[J]. Int J Clin Pharm, 2020.[Online ahead of print]
|
|
[24] XU P, HU YY, YUAN HY, et al. The impact of a training program on clinical pharmacists on pharmacy clinical services in a tertiary hospital in hunan China[J]. J Multidiscip Healthc,2019, 12:975-980.
|
|
[25] XIAO N, WANG JW. Thinking of pharmacists introducing big data:Innovation of chronic disease management mode[J].China Pharm, 2016, 27(22):3158-3160.(in Chinese）肖宁，王家伟．药师将互联网大数据引入慢病管理模式的创新思考[J]．中国药房，2016, 27(22):3158-3160.
|
|
[26] CUI Y, MORIYAMA M, CHAYAMA K, et al. Efficacy of a selfmanagement program in patients with chronic viral hepatitis in China[J]. BMC Nurs, 2019, 18:44.
|
|
[27] BOULHOSA RS, OLIVEIRA LP, JESUS RP, et al. The impact of nutritional supplementation on quality of life in patients infected with hepatitis C virus[J]. J Hum Nutr Diet, 2013, 26(Suppl 1):7-15.
|
|
[28] EGUCHI Y, MIZUTA T, ISHIBASHI E, et al. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation[J]. Liver Int, 2009, 29(2):213-220.
|
|
[29] PATTULLO V, DUARTE-ROJO A, SOLIMAN W, et al. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C[J]. Liver Int, 2013, 33(3):410-419.
|
|
[30] IWANE S, MIZUTA T, KAWAGUCHI Y, et al. Impact of body weight reduction via diet and exercise on the anti-viral effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with insulin resistance:A randomized controlled pilot trial[J]. Intern Med, 2015, 54(24):3113-3119.
|
|
[31] SUBLETTE VA, DOUGLAS MW, MCCAFFERY K, et al. Psychological, lifestyle and social predictors of hepatitis C treatment response:A systematic review[J]. Liver Int, 2013, 33(6):894-903.
|
|
[32] KIM K, CHOI S, PARK SM. Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus infection:A Korean population-based cohort study[J]. JAMA Oncol, 2018, 4(5):737-739.
|
|
[33] IIDA-UENO A, ENOMOTO M, TAMORI A, et al. Hepatitis B virus infection and alcohol consumption[J]. World J Gastroenterol, 2017, 23(15):2651-2659.
|
|
[34] MAGRI MC, NUNES A, DANTAS BP, et al. Meta-analysis of the prevalence of HBV infection among alcohol users worldwide[J]. Alcohol Alcohol, 2020, 55(2):136-143.
|
|
[35] CHUANG SC, LEE YC, HASHIBE M, et al. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer:A meta-analysis[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(5):1261-1268.
|
DownLoad: